康希諾(688185.SH):擬出資1.4億元參設私募基金 重點投資疫苗等生物醫藥領域上游產業鏈
格隆匯4月21日丨康希諾(688185.SH)公佈,公司、公司全資子公司博邁(天津)創業投資管理有限公司(簡稱“博邁創投”與天津千汐投資管理合夥企業(有限合夥)(簡稱“天津千汐”)及其他合夥人簽署《元希海河(天津)生物醫藥產業基金合夥企業(有限合夥)有限合夥協議》,共同出資發起設立私募基金,重點投資疫苗等生物醫藥領域的上游產業鏈和創新技術平台的天使輪之後的投資標的。本次投資設立的基金目標募集規模上限人民幣5億元,公司以自有資金認繳出資1.4億元人民幣,出資比例約28%。公司對其他投資人無保底收益、退出擔保等或有義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.